{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Padmapriyadarsini C"],"funding":["India TB Research Consortium - Indian Coucnil of Medical Research","World Health Organization","Open source Pharma Foundation"],"pagination":["e024363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6429929"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["<h4>Introduction</h4>Shorter duration of treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study's objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in comparison to the standard 6-month ATT regimen in the treatment of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB.<h4>Methods and analysis</h4>We are conducting a multicentric, randomised open-label controlled clinical trial to achieve the study objective. The intervention group will receive isoniazid (H), rifampicin ("],"journal":["BMJ open"],"pubmed_title":["Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial."],"pmcid":["PMC6429929"],"funding_grant_id":["001"],"pubmed_authors":["Natrajan M","Guleria R","Padmapriyadarsini C","Kumar H","Swaminathan S","Jawahar SM","Singh M","Gomathy SN","Bhavani PK","Ponnuraja C","Balganesh T"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.","description":"<h4>Introduction</h4>Shorter duration of treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study's objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in comparison to the standard 6-month ATT regimen in the treatment of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB.<h4>Methods and analysis</h4>We are conducting a multicentric, randomised open-label controlled clinical trial to achieve the study objective. The intervention group will receive isoniazid (H), rifampicin (","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-05-07T05:54:30.463Z","creation":"2019-08-04T07:38:07Z"},"accession":"S-EPMC6429929","cross_references":{"pubmed":["30826761"],"doi":["10.1136/bmjopen-2018-024363"]}}